Skip to main content Accessibility help
×
Home
Imaging Dopamine
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 9
  • Export citation
  • Recommend to librarian
  • Buy the print book

Book description

Since its discovery 50 years ago, brain dopamine has been implicated in the control of movement and cognition, and is concerned with diverse brain diseases such as Parkinson's disease, schizophrenia and drug addiction. This book is an illustrated biography of the dopamine molecule, from its synthesis in the brain to its signalling mechanisms and ultimately to its metabolic breakdown. Using colour illustrations of positron emission tomography (PET) scans, each chapter presents a specific stage in the biochemical pathway for dopamine. Writing for researchers and graduate students, Paul Cumming presents a compilation of all that has been learned about dopamine through molecular imaging, a technology which allows the measurement of formerly invisible processes in the living brain. He reviews current technical controversies in the interpretation of dopamine imaging, and presents key results illuminating brain dopamine in illness and health.

Refine List

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Send to Kindle
  • Send to Dropbox
  • Send to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
×

Contents

References
Aalto, S., Hirvonen, J., Kajander, J., Scheinin, H., Nagren, K., Vilkman, H., Gustafsson, L., Syvalahti, E., & Hietala, J. 2002, “Ketamine does not decrease striatal dopamine D2 receptor binding in man”, Psychopharmacology (Berl), vol. 164, no. 4, pp. 401–406.
Abdolmaleky, H. M., Cheng, K. H., Faraone, S. V., Wilcox, M., Glatt, S. J., Gao, F., Smith, C. L., Shafa, R., Aeali, B., Carnevale, J., Pan, H., Papageorgis, P., Ponte, J. F., Sivaraman, V., Tsuang, M. T., & Thiagalingam, S. 2006, “Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder”, Hum. Mol. Genet., vol. 15, no. 21, pp. 3132–3145.
Abe, K., Hosoi, R., Momosaki, S., Kobayashi, K., Ibii, N., & Inoue, O. 2002, “Increment of in vivo binding of [3H]SCH 23390, a dopamine D1 receptor ligand, induced by cyclic AMP-dependent protein kinase in rat brain”, Brain Res., vol. 952, no. 2, pp. 211–217.
Abi-Dargham, A., Gandelman, M. S., DeErausquin, G. A., Zea-Ponce, Y., Zoghbi, S. S., Baldwin, R. M., Laruelle, M., Charney, D. S., Hoffer, P. B., Neumeyer, J. L., & Innis, R. B. 1996, “SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT”, J. Nucl. Med., vol. 37, no. 7, pp. 1129–1133.
Abi-Dargham, A., Kegeles, L. S., Zea-Ponce, Y., Mawlawi, O., Martinez, D., Mitropoulou, V., O'Flynn, K., Koenigsberg, H. W., Heertum, R., Cooper, T., Laruelle, M., & Siever, L. J. 2004, “Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide”, Biol.Psychiatry, vol. 55, no. 10, pp. 1001–1006.
Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., Hwang, D. R., Keilp, J., Kochan, L., Heertum, R., Gorman, J. M., & Laruelle, M. 2002, “Prefrontal dopamine D1 receptors and working memory in schizophrenia”, J. Neurosci., vol. 22, no. 9, pp. 3708–3719.
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Heertum, R. L., Gorman, J. M., & Laruelle, M. 2000, “Increased baseline occupancy of D2 receptors by dopamine in schizophrenia”, Proc. Natl. Acad. Sci. USA, vol. 97, no. 14, pp. 8104–8109.
Abi-Dargham, A., Simpson, N., Kegeles, L., Parsey, R., Hwang, D. R., Anjilvel, S., Zea-Ponce, Y., Lombardo, I., Heertum, R., Mann, J. J., Foged, C., Halldin, C., & Laruelle, M. 1999, “PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756”, Synapse, vol. 32, no. 2, pp. 93–109.
Adams, F., Schwarting, R. K., Boix, F., & Huston, J. P. 1991, “Lateralized changes in behavior and striatal dopamine release following unilateral tactile stimulation of the perioral region: a microdialysis study”, Brain Res., vol. 553, no. 2, pp. 318–322.
Adams, J. R., Netten, N. H., Schulzer, M., Mak, E., Mckenzie, J., Strongosky, A., Sossi, V., Ruth, T. J., Lee, C. S., Farrer, M., Gasser, T., Uitti, R. J., Calne, D. B., Wszolek, Z. K., & Stoessl, A. J. 2005, “PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation”, Brain, vol. 128 (Pt 12), pp. 2777–2785.
Adell, A. & Myers, R. D. 1995, “Synthesis of dopamine and 5-HT in anatomical regions of the rat's brain is unaffected by sustained infusion of amperozide”, Pharmacol. Toxicol., vol. 77, no. 5, pp. 341–345.
Agnati, L. F., Ferre, S., Burioni, R., Woods, A., Genedani, S., Franco, R., & Fuxe, K. 2005, “Existence and theoretical aspects of homomeric and heteromeric dopamine receptor complexes and their relevance for neurological diseases”, Neuromolecular. Med., vol. 7, no. 1–2, pp. 61–78.
Ahlenius, S., Ericson, E., & Wijkstrom, A. 1993, “Stimulation of brain dopamine autoreceptors by remoxipride administration in reserpine-treated male rats”, J. Pharm. Pharmacol., vol. 45, no. 3, pp. 237–239.
Ahlenius, S. & Salmi, P. 1994, “Behavioral and biochemical effects of the dopamine D3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat”, Eur. J. Pharmacol., vol. 260, no. 2–3, pp. 177–181.
Ahnert-Hilger, G., Nurnberg, B., Exner, T., Schafer, T., & Jahn, R. 1998, “The heterotrimeric G protein Go2 regulates catecholamine uptake by secretory vesicles”, EMBO J., vol. 17, no. 2, pp. 406–413.
Aiso, M., Shigematsu, K., Kebabian, J. W., Potter, W. Z., Cruciani, R. A., & Saavedra, J. M. 1987, “Dopamine D1 receptor in rat brain: a quantitative autoradiographic study with 125I-SCH 23982”, Brain Res., vol. 408, no. 1–2, pp. 281–285.
Albert, K. A., Helmer-Matyjek, E., Nairn, A. C., Muller, T. H., Haycock, J. W., Greene, L. A., Goldstein, M., & Greengard, P. 1984, “Calcium/phospholipid-dependent protein kinase (protein kinase C) phosphorylates and activates tyrosine hydroxylase”, Proc. Natl. Acad. Sci. USA, vol. 81, no. 24, pp. 7713–7717.
Albert, K. A., Hemmings, H. C.., Adamo, A. I., Potkin, S. G., Akbarian, S., Sandman, C. A., Cotman, C. W., Bunney, W. E.., & Greengard, P. 2002, “Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia”, Arch. Gen. Psychiatry, vol. 59, no. 8, pp. 705–712.
Albert, P. R., Neve, K. A., Bunzow, J. R., & Civelli, O. 1990, “Coupling of a cloned rat dopamine-D2 receptor to inhibition of adenylyl cyclase and prolactin secretion”, J. Biol. Chem., vol. 265, no. 4, pp. 2098–2104.
Albert, V. R., Allen, J. M., & Joh, T. H. 1987, “A single gene codes for aromatic L-amino acid decarboxylase in both neuronal and non-neuronal tissues”, J. Biol. Chem., vol. 262, no. 19, pp. 9404–9411.
Albert, V. R., Lee, M. R., Bolden, A. H., Wurzburger, R. J., & Aguanno, A. 1992, “Distinct promoters direct neuronal and nonneuronal expression of rat aromatic L-amino acid decarboxylase”, Proc. Natl. Acad. Sci. USA, vol. 89, no. 24, pp. 12053–12057.
Albin, R. L., Koeppe, R. A., Bohnen, N. I., Nichols, T. E., Meyer, P., Wernette, K., Minoshima, S., Kilbourn, M. R., & Frey, K. A. 2003, “Increased ventral striatal monoaminergic innervation in Tourette syndrome”, Neurology, vol. 61, no. 3, pp. 310–315.
Alexander, G. E. & Crutcher, M. D. 1990, “Functional architecture of basal ganglia circuits: neural substrates of parallel processing”, Trends Neurosci., vol. 13, no. 7, pp. 266–271.
Alia-Klein, N., Goldstein, R. Z., Kriplani, A., Logan, J., Tomasi, D., Williams, B., Telang, F., Shumay, E., Biegon, A., Craig, I. W., Henn, F., Wang, G. J., Volkow, N. D., & Fowler, J. S. 2008, “Brain monoamine oxidase A activity predicts trait aggression”, J. Neurosci., vol. 28, no. 19, pp. 5099–5104.
Almas, B., Bourdelles, B., Flatmark, T., Mallet, J., & Haavik, J. 1992, “Regulation of recombinant human tyrosine hydroxylase isozymes by catecholamine binding and phosphorylation. Structure/activity studies and mechanistic implications”, Eur. J. Biochem., vol. 209, no. 1, pp. 249–255.
Altar, C. A. & Marien, M. R. 1987, “Picomolar affinity of 125I-SCH 23982 for D1 receptors in brain demonstrated with digital subtraction autoradiography”, J. Neurosci., vol. 7, no. 1, pp. 213–222.
Amsterdam, J. D. & Newberg, A. B. 2007, “A preliminary study of dopamine transporter binding in bipolar and unipolar depressed patients and healthy controls”, Neuropsychobiology, vol. 55, no. 3–4, pp. 167–170.
Anand, A., Verhoeff, P., Seneca, N., Zoghbi, S. S., Seibyl, J. P., Charney, D. S., & Innis, R. B. 2000, “Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients”, Am. J. Psychiatry, vol. 157, no. 7, pp. 1108–1114.
Anastasiadis, P. Z., Kuhn, D. M., & Levine, R. A. 1994, “Tetrahydrobiopterin uptake into rat brain synaptosomes, cultured PC12 cells, and rat striatum”, Brain Res., vol. 665, no. 1, pp. 77–84.
Anden, N. E., Rubenson, A., Fuxe, K., & Hokfelt, T. 1967, “Evidence for dopamine receptor stimulation by apomorphine”, J. Pharm. Pharmacol., vol. 19, no. 9, pp. 627–629.
Andersen, P. H. & Braestrup, C. 1986, “Evidence for different states of the dopamine D1 receptor: clozapine and fluperlapine may preferentially label an adenylate cyclase-coupled state of the D1 receptor”, J. Neurochem., vol. 47, no. 6, pp. 1822–1831.
Andrews, T. C., Weeks, R. A., Turjanski, N., Gunn, R. N., Watkins, L. H., Sahakian, B., Hodges, J. R., Rosser, A. E., Wood, N. W., & Brooks, D. J. 1999, “Huntington's disease progression. PET and clinical observations”, Brain, vol. 122 (Pt 12), pp. 2353–2363.
Anstrom, K. K. & Woodward, D. J. 2005, “Restraint increases dopaminergic burst firing in awake rats”, Neuropsychopharmacology, vol. 30, no. 10, pp. 1832–1840.
Antonini, A., Leenders, K. L., Reist, H., Thomann, R., Beer, H. F., & Locher, J. 1993, “Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride”, Arch. Neurol., vol. 50, no. 5, pp. 474–480.
Antonini, A., Schwarz, J., Oertel, W. H., Beer, H. F., Madeja, U. D., & Leenders, K. L. 1994, “[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors”, Neurology, vol. 44, no. 7, pp. 1325–1329.
Antonini, A., Schwarz, J., Oertel, W. H., Pogarell, O., & Leenders, K. L. 1997, “Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride”, Mov. Disord., vol. 12, no. 1, pp. 33–38.
Apud, J. A. & Weinberger, D. R. 2007, “Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors”, CNS Drugs, vol. 21, no. 7, pp. 535–557.
Arai, R., Karasawa, N., Geffard, M., Nagatsu, T., & Nagatsu, I. 1994, “Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase”, Brain Res., vol. 667, no. 2, pp. 295–299.
Arai, R., Kimura, H., & Maeda, T. 1986, “Topographic atlas of monoamine oxidase-containing neurons in the rat brain studied by an improved histochemical method”, Neuroscience, vol. 19, no. 3, pp. 905–925.
Araki, T., Tanji, H., Kato, H., Imai, Y., Mizugaki, M., & Itoyama, Y. 2000, “Temporal changes of dopaminergic and glutamatergic receptors in 6-hydroxydopamine-treated rat brain”, Eur. Neuropsychopharmacol., vol. 10, no. 5, pp. 365–375.
Ariano, M. A., Sortwell, C. E., Ray, M., Altemus, K. L., Sibley, D. R., & Levine, M. S. 1997, “Agonist-induced morphologic decrease in cellular D1A dopamine receptor staining”, Synapse, vol. 27, no. 4, pp. 313–321.
Arias-Montano, J. A., Martinez-Fong, D., & Aceves, J. 1991, “Gamma-aminobutyric acid (GABAB) receptor-mediated inhibition of tyrosine hydroxylase activity in the striatum of rat”, Neuropharmacology, vol. 30, no. 10, pp. 1047–1051.
Arias-Montano, J. A., Martinez-Fong, D., & Aceves, J. 1992, “GABAB receptor activation partially inhibits N-methyl-D-aspartate-mediated tyrosine hydroxylase stimulation in rat striatal slices”, Eur. J. Pharmacol., vol. 218, no. 2–3, pp. 335–338.
Arnett, C. D., Fowler, J. S., MacGregor, R. R., Schlyer, D. J., Wolf, A. P., Langstrom, B., & Halldin, C. 1987, “Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-[11C]deprenyl”, J. Neurochem., vol. 49, no. 2, pp. 522–527.
Asanuma, K., Ma, Y., Okulski, J., Dhawan, V., Chaly, T., Carbon, M., Bressman, S. B., & Eidelberg, D. 2005, “Decreased striatal D2 receptor binding in non-manifesting carriers of the DYT1 dystonia mutation”, Neurology, vol. 64, no. 2, pp. 347–349.
Asselin, M. C., Montgomery, A. J., Grasby, P. M., & Hume, S. P. 2007, “Quantification of PET studies with the very high-affinity dopamine D2/D3 receptor ligand [11C]FLB 457: re-evaluation of the validity of using a cerebellar reference region”, J. Cereb. Blood Flow Metab., vol. 27, no. 2, pp. 378–392.
Atkinson, J., Richtand, N., Schworer, C., Kuczenski, R., & Soderling, T. 1987, “Phosphorylation of purified rat striatal tyrosine hydroxylase by Ca2+/calmodulin-dependent protein kinase II: effect of an activator protein”, J. Neurochem., vol. 49, no. 4, pp. 1241–1249.
Atsumi, M., Kawakami, J., Sugiyama, E., Kotaki, H., Sawada, Y., Sato, H., Yamada, Y., & Iga, T. 2003, “Pharmacokinetic and pharmacodynamic analyses, based on dopamine D2-receptor occupancy of bromocriptine, of bromocriptine-induced contralateral rotations in unilaterally 6-OHDA-lesioned rats”, Synapse, vol. 50, no. 2, pp. 110–116.
Aubert, I., Ghorayeb, I., Normand, E., & Bloch, B. 2000, “Phenotypical characterization of the neurons expressing the D1 and D2 dopamine receptors in the monkey striatum”, J. Comp. Neurol., vol. 418, no. 1, pp. 22–32.
Axelrod, J. & Tomchick, R. 1958, “Enzymatic O-methylation of epinephrine and other catechols”, J. Biol. Chem., vol. 233, no. 3, pp. 702–705.
Azzaro, A. J., King, J., Kotzuk, J., Schoepp, D. D., Frost, J., & Schochet, S. 1985, “Guinea pig striatum as a model of human dopamine deamination: the role of monoamine oxidase isozyme ratio, localization, and affinity for substrate in synaptic dopamine metabolism”, J. Neurochem., vol. 45, no. 3, pp. 949–956.
Bach, A. W., Lan, N. C., Johnson, D. L., Abell, C. W., Bembenek, M. E., Kwan, S. W., Seeburg, P. H., & Shih, J. C. 1988, “cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties”, Proc. Natl. Acad. Sci. USA, vol. 85, no. 13, pp. 4934–4938.
Backman, L., Ginovart, N., Dixon, R. A., Wahlin, T. B., Wahlin, A., Halldin, C., & Farde, L. 2000, “Age-related cognitive deficits mediated by changes in the striatal dopamine system”, Am. J. Psychiatry, vol. 157, no. 4, pp. 635–637.
Badgaiyan, R. D., Fischman, A. J., & Alpert, N. M. 2003, “Striatal dopamine release during unrewarded motor task in human volunteers”, Neuroreport, vol. 14, no. 11, pp. 1421–1424.
Badgaiyan, R. D., Fischman, A. J., & Alpert, N. M. 2007, “Striatal dopamine release in sequential learning”, Neuroimage, vol. 38, no. 3, pp. 549–556.
Badgaiyan, R. D., Fischman, A. J., & Alpert, N. M. 2008, “Explicit motor memory activates the striatal dopamine system”, Neuroreport, vol. 19, no. 4, pp. 409–412.
Ballesteros, J., Maeztu, A. I., Callado, L. F., Meana, J. J., & Gutiérrez, M. 2008, “Specific binding of [3H]Ro 19-6327 (lazabemide) to monoamine oxidase B is increased in frontal cortex of suicide victims after controlling for age at death”, Eur. Neuropsychopharmacol., vol. 18, no. 1, pp. 55–61.
Bancroft, G. N., Morgan, K. A., Flietstra, R. J., & Levant, B. 1998, “Binding of [3H]PD 128907, a putatively selective ligand for the D3 dopamine receptor, in rat brain: a receptor binding and quantitative autoradiographic study”, Neuropsychopharmacology, vol. 18, no. 4, pp. 305–316.
Bannon, M. J. & Roth, R. H. 1983, “Pharmacology of mesocortical dopamine neurons”, Pharmacol. Rev., vol. 35, no. 1, pp. 53–68.
Bantick, R. A., Vries, M. H., & Grasby, P. M. 2005, “The effect of a 5-HT1A receptor agonist on striatal dopamine release”, Synapse, vol. 57, no. 2, pp. 67–75.
Baran, H. & Jellinger, K. 1992, “Human brain phenolsulfotransferase. Regional distribution in Parkinson's disease”, J. Neural. Transm. Park. Dis. Dement. Sect., vol. 4, pp. 267–276.
Barbeau, A., Sourkes, T. L., & Murphy, G. F. 1962, “[Les catécholamines dans la maladie to Parkinson],” in Monoamines et système nerveux central, Ajuriaguerra, J., ed., Georg & Cie SA, Geneva, pp. 247–262.
Barbier, P., Colelli, A., Maggio, R., Bravi, D., & Corsini, G. U. 1997, “Pergolide binds tightly to dopamine D2 short receptors and induces receptor sequestration”, J. Neural. Transm., vol. 104, no. 8–9, pp. 867–874.
Barnes, J. M., Barnes, N. M., Costall, B., & Naylor, R. J. 1990, “The actions of (-)N-n-propylnorapomorphine and selective dopamine D1 and D2 receptor agonists to modify the release of [3H]dopamine from the rat nucleus accumbens”, Neuropharmacology, vol. 29, no. 4, pp. 327–336.
Baron, J. C., Maziere, B., Loc'h, C., Cambon, H., Sgouropoulos, P., Bonnet, A. M., & Agid, Y. 1986, “Loss of striatal [76Br]bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy”, J. Cereb. Blood Flow Metab., vol. 6, no. 2, pp. 131–136.
Barrett, S. P., Boileau, I., Okker, J., Pihl, R. O., & Dagher, A. 2004, “The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride”, Synapse, vol. 54, no. 2, pp. 65–71.
Barrio, J. R., Huang, S. C., & Phelps, M. E. 1997, “Biological imaging and the molecular basis of dopaminergic diseases”, Biochem. Pharmacol., vol. 54, no. 3, pp. 341–348.
Bart, J., Willemsen, A. T., Groen, H. J., Graaf, W. T., Wegman, T. D., Vaalburg, W., Vries, E. G., & Hendrikse, N. H. 2003, “Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET”, Neuroimage, vol. 20, no. 3, pp. 1775–1782.
Baumann, M. H., Raley, T. J., Partilla, J. S., & Rothman, R. B. 1993, “Biosynthesis of dopamine and serotonin in the rat brain after repeated cocaine injections: a microdissection mapping study”, Synapse, vol. 14, no. 1, pp. 40–50.
Bean, A. J., Shepard, P. D., Bunney, B. S., Nestler, E. J., & Roth, R. H. 1988, “The effects of pertussis toxin on autoreceptor-mediated inhibition of dopamine synthesis in the rat striatum”, Mol. Pharmacol., vol. 34, no. 6, pp. 715–718.
Bench, C. J., Price, G. W., Lammertsma, A. A., Cremer, J. C., Luthra, S. K., Turton, D., Dolan, R. J., Kettler, R., Dingemanse, J., Da Prada, M., et al. 1991, “Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327”, Eur. J. Clin. Pharmacol., vol. 40, no. 2, pp. 169–173.
Bendayan, R., Ronaldson, P. T., Gingras, D., & Bendayan, M. 2006, “In situ localization of P-glycoprotein (ABCB1) in human and rat brain”, J. Histochem. Cytochem., vol. 54, no. 10, pp. 1159–1167.
Bennett, B. A. & Freed, C. R. 1986, “Mobilization of storage pool dopamine and late ipsilateral augmentation of striatal dopamine synthesis in the trained circling rat”, J. Neurochem., vol. 47, no. 2, pp. 472–476.
Benveniste, H., Hansen, A. J., & Ottosen, N. S. 1989, “Determination of brain interstitial concentrations by microdialysis”, J. Neurochem., vol. 52, no. 6, pp. 1741–1750.
Benwell, M. E. & Balfour, D. J. 1992, “The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity”, Br. J. Pharmacol., vol. 105, no. 4, pp. 849–856.
Berding, G., Brucke, T., Odin, P., Brooks, D. J., Kolbe, H., Gielow, P., Harke, H., Knoop, B. O., Dengler, R., & Knapp, W. H. 2003, “[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy”, Nuklearmedizin, vol. 42, no. 1, pp. 31–38.
Bergstrom, M., Kumlien, E., Lilja, A., Tyrefors, N., Westerberg, G., & Langstrom, B. 1998, “Temporal lobe epilepsy visualized with PET with 11C-L-deuterium-deprenyl – analysis of kinetic data”, Acta Neurol. Scand., vol. 98, no. 4, pp. 224–231.
Bergstrom, M., Westerberg, G., & Langstrom, B. 1997, “11C-harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies”, Nucl. Med. Biol., vol. 24, no. 4, pp. 287–293.
Bergstrom, M., Westerberg, G., Nemeth, G., Traut, M., Gross, G., Greger, G., Muller-Peltzer, H., Safer, A., Eckernas, S. A., Grahner, A., & Langstrom, B. 1997, “MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography”, Eur. J. Clin. Pharmacol., vol. 52, no. 2, pp. 121–128.
Berretta, S., Sachs, Z., & Graybiel, A. M. 1999, “Cortically driven Fos induction in the striatum is amplified by local dopamine D2-class receptor blockade”, Eur. J. Neurosci., vol. 11, no. 12, pp. 4309–4319.
Best, S. E., Sarrel, P. M., Malison, R. T., Laruelle, M., Zoghbi, S. S., Baldwin, R. M., Seibyl, J. P., Innis, R. B., & Dyck, C. H. 2005, “Striatal dopamine transporter availability with [123I]beta-CIT SPECT is unrelated to gender or menstrual cycle”, Psychopharmacology (Berl), vol. 183, no. 2, pp. 181–189.
Bezin, L., Marcel, D., Garcia, C., Blum, D., Lafargue, P., Lellouche, J. P., Pujol, J. F., & Weissmann, D. 2000, “In situ examination of tyrosine hydroxylase activity in the rat locus coeruleus using (3',5')-[(3)H(2)]-alpha-fluoromethyl-tyrosine as substrate of the enzyme”, Synapse, vol. 35, no. 3, pp. 201–211.
Bibb, J. A., Snyder, G. L., Nishi, A., Yan, Z., Meijer, L., Fienberg, A. A., Tsai, L. H., Kwon, Y. T., Girault, J. A., Czernik, A. J., Huganir, R. L., Hemmings, H. C.., Nairn, A. C., & Greengard, P. 1999, “Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons”, Nature, vol. 402, no. 6762, pp. 669–671.
Birrell, C. E. & Balfour, D. J. 1998, “The influence of nicotine pretreatment on mesoaccumbens dopamine overflow and locomotor responses to D-amphetamine”, Psychopharmacology (Berl), vol. 140, no. 2, pp. 142–149.
Biswas, B. & Carlsson, A. 1978, “On the mode of action of diazepam on brain catecholamine metabolism”, Naunyn Schmiedebergs Arch. Pharmacol., vol. 303, no. 1, pp. 73–78.
Blennow, K., Wallin, A., Gottfries, C. G., Karlsson, I., Mansson, J. E., Skoog, I., Wikkelso, C., & Svennerholm, L. 1993, “Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18–88 years of age”, Eur.Neuropsychopharmacol., vol. 3, no. 1, pp. 55–61.
Blomqvist, O., Engel, J. A., Nissbrandt, H., & Soderpalm, B. 1993, “The mesolimbic dopamine-activating properties of ethanol are antagonized by mecamylamine”, Eur. J. Pharmacol., vol. 249, no. 2, pp. 207–213.
Bohnen, N. I., Albin, R. L., Frey, K. A., & Fink, J. K. 1999, “(+)-alpha-[11C]dihydrotetrabenazine PET imaging in familial paroxysmal dystonic choreoathetosis”, Neurology, vol. 52, no. 5, pp. 1067–1069.
Bohnen, N. I., Albin, R. L., Koeppe, R. A., Wernette, K. A., Kilbourn, M. R., Minoshima, S., & Frey, K. A. 2006, “Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease”, J. Cereb. Blood Flow Metab., vol. 26, no. 9, pp. 1198–1212.
Bohnen, N. I., Koeppe, R. A., Meyer, P., Ficaro, E., Wernette, K., Kilbourn, M. R., Kuhl, D. E., Frey, K. A., & Albin, R. L. 2000, “Decreased striatal monoaminergic terminals in Huntington disease”, Neurology, vol. 54, no. 9, pp. 1753–1759.
Bohnen, N. I., Kuwabara, H., Constantine, G. M., Mathis, C. A., & Moore, R. Y. 2007, “Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease”, Neurosci. Lett., vol. 424, no. 3, pp. 185–189.
Boileau, I., Assaad, J. M., Pihl, R. O., Benkelfat, C., Leyton, M., Diksic, M., Tremblay, R. E., & Dagher, A. 2003, “Alcohol promotes dopamine release in the human nucleus accumbens”, Synapse, vol. 49, no. 4, pp. 226–231.
Boileau, I., Dagher, A., Leyton, M., Gunn, R. N., Baker, G. B., Diksic, M., & Benkelfat, C. 2006, “Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men”, Arch. Gen. Psychiatry, vol. 63, no. 12, pp. 1386–1395.
Boileau, I., Dagher, A., Leyton, M., Welfeld, K., Booij, L., Diksic, M., & Benkelfat, C. 2007, “Conditioned dopamine release in humans: a positron emission tomography [11C]raclopride study with amphetamine”, J. Neurosci., vol. 27, no. 15, pp. 3998–4003.
Booij, J., Bergmans, P., Winogrodzka, A., Speelman, J. D., & Wolters, E. C. 2001, “Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease”, Synapse, vol. 39, no. 2, pp. 101–108.
Booij, J., Bruin, K., & Gunning, W. B. 2006, “Repeated administration of D-amphetamine induces loss of [123I]FP-CIT binding to striatal dopamine transporters in rat brain: a validation study”, Nucl. Med. Biol., vol. 33, no. 3, pp. 409–411.
Booij, J., Jong, J., Bruin, K., Knol, R., Win, M. M., & Eck-Smit, B. L. 2007, “Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects”, J. Nucl. Med., vol. 48, no. 3, pp. 359–366.
Borbely, K., Brooks, R. A., Wong, D. F., Burns, R. S., Cumming, P., Gjedde, A., & Di, C. G. 1999, “NMSP binding to dopamine and serotonin receptors in MPTP-induced parkinsonism: relation to dopa therapy”, Acta Neurol. Scand., vol. 100, no. 1, pp. 42–52.
Borghammer, P., Kumakura, Y., & Cumming, P. 2005, “Fluorodopa F 18 positron emission tomography and the progression of Parkinson disease”, Arch. Neurol., vol. 62, no. 9, pp. 1480–1481.
Bottlaender, M., Dolle, F., Guenther, I., Roumenov, D., Fuseau, C., Bramoulle, Y., Curet, O., Jegham, J., Pinquier, J. L., George, P., & Valette, H. 2003, “Mapping the cerebral monoamine oxidase type A: positron emission tomography characterization of the reversible selective inhibitor [11C]befloxatone”, J. Pharmacol. Exp. Ther., vol. 305, no. 2, pp. 467–473.
Bouchard, S. & Roberge, A. G. 1979, “Biochemical properties and kinetic parameters of dihydroxyphenylalanine – 5-hydroxytryptophan decarboxylase in brain, liver, and adrenals of cat”, Can. J. Biochem., vol. 57, no. 7, pp. 1014–1018.
Boulton, A. A. & Juorio, A. V. 1983, “Cerebral decarboxylation of meta- and para-tyrosine”, Experientia, vol. 39, no. 2, pp. 130–134.
Bouthenet, M. L., Souil, E., Martres, M. P., Sokoloff, P., Giros, B., & Schwartz, J. C. 1991, “Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA”, Brain Res., vol. 564, no. 2, pp. 203–219.
Bowers, M. B.., Heninger, G. R., & Gerbode, F. 1969, “Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in psychiatric patients”, Int. J. Neuropharmacol., vol. 8, no. 3, pp. 255–262.
Boyes, B. E., Cumming, P., Martin, W. R., & McGeer, E. G. 1986, “Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects”, Life Sci., vol. 39, no. 23, pp. 2243–2252.
Bracha, H. S., Seitz, D. J., Otemaa, J., & Glick, S. D. 1987, “Rotational movement (circling) in normal humans: sex difference and relationship to hand, foot and eye preference”, Brain Res., vol. 411, no. 2, pp. 231–235.
Brake, W. G., Zhang, T. Y., Diorio, J., Meaney, M. J., & Gratton, A. 2004, “Influence of early postnatal rearing conditions on mesocorticolimbic dopamine and behavioural responses to psychostimulants and stressors in adult rats”, Eur. J. Neurosci., vol. 19, no. 7, pp. 1863–1874.
Breier, A., Kestler, L., Adler, C., Elman, I., Wiesenfeld, N., Malhotra, A., & Pickar, D. 1998, “Dopamine D2 receptor density and personal detachment in healthy subjects”, Am. J. Psychiatry, vol. 155, no. 10, pp. 1440–1442.
Breier, A., Su, T. P., Saunders, R., Carson, R. E., Kolachana, B. S., Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., & Pickar, D. 1997, “Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method”, Proc. Natl. Acad. Sci. USA, vol. 94, no. 6, pp. 2569–2574.
Bressan, R. A., Erlandsson, K., Jones, H. M., Mulligan, R., Flanagan, R. J., Ell, P. J., & Pilowsky, L. S. 2003, “Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients”, Am. J. Psychiatry, vol. 160, no. 8, pp. 1413–1420.
Brodie, B. B., Costa, E., Dlabac, A., Neff, N. H., & Smookler, H. H. 1966, “Application of steady state kinetics to the estimation of synthesis rate and turnover time of tissue catecholamines”, J. Pharmacol. Exp. Ther., vol. 154, no. 3, pp. 493–498.
Brody, A. L., Mandelkern, M. A., Olmstead, R. E., Allen-Martinez, Z., Scheibal, D., Abrams, A. L., Costello, M. R., Farahi, J., Saxena, S., Monterosso, J., & London, E. D. 2008, “Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette”, Neuropsychopharmacology [Epub ahead of print].
Brody, A. L., Mandelkern, M. A., Olmstead, R. E., Scheibal, D., Hahn, E., Shiraga, S., Zamora-Paja, E., Farahi, J., Saxena, S., London, E. D., & McCracken, J. T. 2006, “Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens”, Arch. Gen. Psychiatry, vol. 63, no. 7, pp. 808–816.
Brody, A. L., Olmstead, R. E., London, E. D., Farahi, J., Meyer, J. H., Grossman, P., Lee, G. S., Huang, J., Hahn, E. L., & Mandelkern